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Abstract  
Cluster randomized trial designs are growing in popularity in, for example, 
cardiovascular medicine research and other clinical areas and parallel statistical 
developments concerned with the design and analysis of these trials have been 
stimulated.  Nevertheless, reviews suggest that design issues associated with cluster 
randomized trials are often poorly appreciated and there remain inadequacies in, for 
example, describing how the trial size is determined and the associated results are 
presented.  In this paper, our aim is to provide pragmatic guidance for researchers on the 
methods of calculating sample sizes.  We focus attention on designs with the primary 
purpose of comparing two interventions with respect to continuous, binary, ordered 
categorical, incidence rate and time-to-event outcome variables.  Issues of aggregate and 
non-aggregate cluster trials, adjustment for variation in cluster size and the effect size are 
detailed.  The problem of establishing the anticipated magnitude of between- and within-
cluster variation to enable planning values of the intra-cluster correlation coefficient and 
the coefficient of variation are also described.  Illustrative examples of calculations of 
trial sizes for each endpoint type are included.  [Word count: 184175] 
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INTRODUCTION 
In contrast to clinical trials in which individual subjects are each randomized to receive 
one of the therapeutic options or interventions under test, the distinctive characteristic of 
a cluster trial is that specific groups or blocks of subjects (the clusters) are first identified 
and these units DUH DVVLJQHGDW UDQGRP WR WKH LQWHUYHQWLRQV 7KH WHUP³FOXVWHU´ LQ WKLV
context may be a household, school, clinic, care home or any other relevant grouping of 
individuals.  When comparing the interventions in such cluster randomized trials, 
account must always be made of the particular cluster from which the data item is 
obtained. 
A large and ever increasing number of cluster randomized trials have been conducted 
or are underway covering many aspects of cardiovascular related medicine.  These 
include trials of cardiovascular guidelines [1], prescribing practice [2], community health 
awareness [3], breast feeding promotion on cardiometabolic risk factors in childhood [4], 
the effectiveness of a multifactorial intervention to improve both medication adherence 
and blood pressure control and to reduce cardiovascular events [5], and improving 
outcomes in patients with left ventricular systolic dysfunction [6].  In the TEACH trial of 
local pharmacy support [7], the clusters were the local pharmacists of patients with heart 
failure (HF) who had been hospitalised and then discharged into the community.  The 
plan was that clusters were each randomized to one of the two interventions on a 1:1 
basis: CONTROL or PHARM.  Those pharmacists allocated PHARM would give their 
patients additional educational (motivational) support.  Hence, all the patients within a 
particular cluster received the same intervention.  A patient experiencing any one of a 
readmission, emergency room visit or mortality due to HF was regarded as a failure.   
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There are numerous publications describing design, analysis and reporting issues 
concerned with cluster randomized trials, including text books [8-11].  However much of 
the literature is fragmented and some quite old (though still relevant).  Further some of 
the articles are quite technical in nature so investigators may find it difficult to determine 
best practice.  A review of cluster trials [12], published subsequent to the 2004 extension 
of the CONSORT guidelines [13-14], concluded that the methodological quality of 
cluster trials often remains suboptimal.  
To facilitate and improve this situation, we focus on methods of determining the 
number of subjects (and clusters) required with the aim to provide a compact but 
comprehensive reference for those designing cluster trials. [Word count: 390] 
GENERAL DESIGN CONSIDERATIONS 
Individually randomized trials ± continuous outcome measure 
At the close of a clinical trial, and once all the data collection is complete, a comparison 
will be made between the interventions with respect to the primary endpoint.  For the 
case of two interventions, Standard (S) and Test (T), with nS and nT patients respectively 
randomized individually to each, the statistical process for a continuous outcome 
measure, y, is made by comparing the corresponding means ݕതௌ and ݕത் by use of 
6WXGHQW¶Vt-test.  This tests the null hypothesis that the difference į = ȝT ± ȝS =  0, where 
ȝS and ȝT are the true or population means of interventions S and T.  If the null hypothesis 
is rejected then we conclude ȝS and ȝT differ. 
However, prior to this analysis, the trial must first be designed and conducted.  In 
general, critical decisions to be made by the design team are the choice (and number) of 
interventions to compare and the endpoint measure which will be used for the evaluation.  
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A vital detail is the difference in the outcome (the effect size or įPlan) between the 
randomized interventions which might be anticipated.  Such a difference should be one 
(if established) of sufficient clinical importance to justify the expense of conducting the 
planned trial and likely to lead to changes in clinical practice.  Also required is the 
standard deviation (SD), ıPlan, of the endpoint variable of concern.  A further design 
option is the choice of the ratio of subjects 1: ĳ allocated to S and T respectively (see 
below).   
Once these aspects are provided, the numbers of subjects to be randomized to each 
intervention for a continuous endpoint is [15]: ݊ௌ ൌ ቀଵାఝఝ ቁ ൫௭భషഀȀమା௭భషഁ൯మሺఋು೗ೌ೙Ȁఙು೗ೌ೙ሻమ ൅ ൤ ௭భషഀȀమమଶሺଵାఝሻ൨, ்݊ ൌ ߮݊ௌ                        (1) 
giving a total N = nS + nT.  
Here, Į is the Type I error which is the required probability of rejecting the null 
K\SRWKHVLVZKHQIDOVHO\GHFODULQJµA difference¶EHWZHHQWKHLQWHUYHQWLRQVand when µNo 
difference¶ is present.  The Type II error ȕ corresponds to the probability of falsely 
accepting the null hypothesis RIµNo difference¶ZKHQ the actual size of the difference is 
indeed įPlan.  The quantity 1  ȕ is known as the power.  
Further, z1-D/2 and z1-E are values with probabilities of D/2 and E respectively in the 
upper tail of the standard Normal distribution.  Typically Į = 0.05 leading to z1-0.05/2 = 
z0.975 = 1.9600 while ȕ = 0.2 or 0.1 leading to z0.8 = 0.8416 and z0.9 = 1.2816 respectively. 
The final term ൤ ௭భషഀȀమమଶሺଵାఝሻ൨ in equation (1) applies only when the sample size is small.  
However, when Į = 0.05 and ĳ = 1, this implies adding ቂ ଵǤଽ଺మଶൈሺଵାଵሻቃ ൌ ଷǤ଼ସଵ଺ସ ൎ  ? unit extra 
to each intervention group.   
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An alternative is first to assume ĳ = 1 in (1), to obtain n subjects for each intervention 
and then calculate the final numbers per intervention using ݊ௌ ൌ ௡ሺଵାఝሻଶఝ , ்݊ ൌ ௡ሺଵାఝሻଶ .                                                 (2) 
This increases the initial total number of subjects N from 2n to  ௡ሺଵାఝሻమଶఝ  which, if ĳ = 0.5, 
implies N = 2.25n.  If, as we will be concerned with later, it is the number of clusters that 
is being calculated then k, kS, kT and K replace the corresponding n¶V 
Cluster randomized trials 
When the randomised allocation applies to the clusters, the basic principles for sample 
size calculation still apply although modifications are required.  To illustrate these we 
first describe the t-test, for comparing two means from a non-cluster design, using linear 
regression terminology with intercept ȝS and slope į, that is,  
yj  ȝS į[İj,                                              (3) 
where the subjects concerned are j = 1, 2, ... , N; x = 0 for S and x = 1 for T.  Further İj is 
a random variable with mean zero and, within each intervention group, assumed to have 
the same variance, ı2.  If this regression model is fitted to the data then ݀ ൌ ݕത் െ ݕതௌ 
estimates į = ȝT ± ȝS and the null hypothesis remains į = 0.  However the analysis must 
now take account of the cluster to which an individual subject belongs.  When we 
compare two interventions N (= nS + nT) patients will be recruited who will come from 
clusters of size m with therefore kS = nS/m, kT = nT/m and K = kS + kT clusters in total.  
To allow for the clusters, model (3) is extended to:  ݕ௜௝ ൌ ߤௌ ൅ ߜݔ ൅ ߛ௜ ൅ ߝ௜௝.                           (4) 
Here the clusters are i  «K and the subjects j  «m in each cluster.  The 
cluster effects, Ȗi, are assumed to vary at random within each intervention about a mean 
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of zero, with a variance, ߪ஻௘௧௪௘௘௡ି஼௟௨௦௧௘௥ଶ .  Further the İij are also assumed to have mean 
zero but with variance, ߪௐ௜௧௛௜௡ି஼௟௨௦௧௘௥ଶ  and both random variables, Ȗ and İ, are assumed 
to be Normally distributed.  The combined sum of the within- and between-cluster 
variances,ߪ்௢௧௔௟ଶ ൌ ߪ஻௘௧௪௘௘௡ି஼௟௨௦௧௘௥ଶ ൅ ߪௐ௜௧௛௜௡ି஼௟௨௦௧௘௥ଶ Ǥ 
Although the format of the (random-effects) model (4) will change depending on the 
outcome measure of concern, all will contain random terms accounting for the cluster 
design.   
The sample size formula (1) is essentially determined as a consequence of model (3) 
while the formulae which follow for cluster trials, are based on (4).   
CLUSTER DESIGN CONSIDERATIONS 
Intra-cluster correlation coefficient (ICC) ± continuous outcome  
A feature of all cluster trials is that subjects recruited from within the same cluster cannot 
be regarded as acting independently of each other in terms of their response to the 
intervention received.  The magnitude of this within-cluster dependence, which 
ultimately influences the eventual trial size, is quantified by the intra-cluster correlation 
coefficient (ICC), ȡ, which is interpreted in a similar way to Pearson correlation.   
With each subject in every cluster providing an outcome measure, the ICC is the 
proportion of the combined sum of the within- and between-cluster variances 2TotalV  
accounted for by the between-cluster variation, that is  
2 2
- -
2 2 2
- -
Between Cluster Between Cluster
Total Between Cluster Within Cluster
V VU V V V   .                         (5) 
Thus, since variances cannot be negative, the ICC cannot be negative.  A major 
challenge in planning the sample size is identifying an appropriate value for ȡ.  In 
practice, estimates of ȡ are usually obtained from previously reported trials using similar 
Sample Size for Cluster Trials 
8 
Cluster01_15Feb13Editor 
randomization units and outcome measures.  The values of U arising in a primary care 
setting tend to vary from 0.01 to 0.05 with a median value quoted as 0.01 [16].  Larger 
ICCs have been reported [17] although for community intervention trials they are 
typically < 0.01 [8].  Our suggestion is to try different values of the ICC and investigate 
how sensitive the sample size estimate is to these changes. 
The Design Effect (DE)  
The impact of the ICC, on the planned trial size, will depend on its magnitude and on the 
number of subjects recruited per cluster, m, through the so-called design effect (DE),   ܦܧ ൌ  ? ൅ሺ݉ െ  ?ሻߩǤ                                                    (5X) 
The DE is then multiplied by the sample size obtained from (say) equation (1) to give that 
required for a cluster design.  In practice there may be substantial variation in m from 
cluster to cluster and to allow for such variation DE becomes: [18] ܦܧ ൌ  ? ൅ ቀ ഥ݉ ൅ሾௌ஽ሺ௠ሻሿమ௠ഥ െ  ?ቁ ߩ,                                      (6) 
where ഥ݉  is the anticipated mean cluster size, and ܵܦሺ݉ሻ the corresponding standard 
deviation.  As the value of DE depends on ȡ, whose value may not be firmly established, 
our suggestion is to try different values of the ICC and investigate how sensitive the 
sample size estimates are to these changes.  In all situations, DE ZLOOEH 1 since m and ഥ݉  > 1 and ȡ    
Another option Van Breukelen and Candel [19] have suggested that if m varies the 
above approach is conservative and a better method is to adjust the total number of 
clusters initially planned, K, to: 
2{1 [ ( )] (1 )}Adjusted
KK
CV m [ [   ,                                      (7) 
Sample Size for Cluster Trials 
9 
Cluster01_15Feb13Editor 
where the coefficient of variation, 
m
mSD
mCV )()(   and )1( UU
U[  m
m
.[19].  
However, since 10  [ , the maximum possible value of 
4
1)1(  [[  and so the largest 
adjustment to K corresponds to 1/{1 ± [CV(m)]2/4}.  Further since the CV(m) is usually 
less than 0.7 the inflation of K necessary to allow for varying m is at most about 14%.  If 
CV(m) = 0.35 then the inflation is at most 3%. 
In general practice, variation in m results in an increase in total sample size for the trial 
and equation (6) tends to overestimate the required sample size .  Hence whether to use 
equation (6) or (7) requires some judgement.  For example, if SD(m) is large it might be 
quite difficult to raise the number of subjects recruited in each cluster to ensure ഥ݉  is 
increased and thereby the requisite (new) total sample size achieved.  In which case, 
increasing K through equation (7) may be the most practical option.  In contrast, In 
situations where increasing ഥ݉  is feasible, equation (6) may suffice.    
Control hypertension and hypercholesterolemia [20] 
To illustrate the impact of varying cluster size on the DE, we use the results from 
STITCH2 trial which includes the precise number of clusters within each intervention 
and the number of subjects recruited per cluster.  Table 1 shows that cluster size varied 
considerably from 2 to 47.  For both interventions combined, CV(m) = 15.29/26.43 = 0.59 
and this magnitude is not atypical.   
Table 1. Number of clusters and the corresponding CV(m) of cluster size by care 
intervention group of the STITCH2 trial (data from Dresser, et al. (2013) [20])  
 CareIntervention N(m) Min(m) ഥ݉  Max(m) SD(m) CV(m)  
Sample Size for Cluster Trials 
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 Guideline 20 2 28.75 47 15.59 0.54  
 STITCH2 15 2 23.33 45 14.83 0.64  
 Total 35 2 26.43 47 15.29 0.59  
 
If m = 26 is taken as the anticipated cluster size in a trial, then from equation (5X), DE 
= 1 + 25ȡ, whereas if information from Table 1 is used equation (6) gives ܦܧ ൌ  ? ൅ቀ ? ?Ǥ ? ?൅ ଵହǤଶଽమଶ଺Ǥସଷ െ  ?ቁ ߩ = 1 + 34.3ȡ which is clearly larger. 
 
Community Based Exercise Programme [21] 
In contrast, a community based exercise programme in over 65 year olds involving K = 
12 practices recruited a mean of ഥ݉  = 535 individuals from each with SD(m) = 139.9 to 
give a much lower figure of CV(m) = 0.26.   
 
When planning a new trial, investigators may be guided by results such as these. 
Potential attrition  
For many different reasons, the eventual numbers of clusters and/or subjects recruited 
may be less than that those planned.   
Clearly, the loss of all information from a cluster has greater impact than the loss of 
(few) patients within a cluster.  Thus, as a precaution, the initial number of clusters, K, 
indicated by the preliminary sample size calculations may need to be increased.  Relevant 
experience of the design group, or reference to published studies reporting such losses, 
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may provide guidance on the extent of potential loss.  Any change in K may lead the 
design team to reconsider m, N or both 
So, In anticipation of this possible subject attrition, the initial plan for the trial size, N, 
can be inflated by the division of the proportion, T, of subjects recruited for whom the 
endpoint measure is likely to be recorded.  However this tends to overestimate the sample 
size required.  An alternative is first to modify the DE using mT in place of m, obtain the 
resulting sample size by the appropriate means, and then divide by T again.  This process 
tends to underestimate the sample size required since it is unlikely that the drop-out rate 
is equal in each cluster and so the cluster size will vary, which results in loss of power 
[11, p67]. Consequently, a compromise sample size mid-way between the two 
approaches may be sought.  Any change in N may lead the design team to alter reconsider 
m, K or both. 
 
The allocation ratio, ĳ  
Although the majority of clinical trials involve equal allocation to each of the 
interventions, there may be circumstances in which the proportions may differ.  Thus, in 
the case of two interventions, nS patients may be allocated to S, while nT (z nS) are 
allocated to T.  In which that case, the allocation ratio, ĳ, is set so nT = ĳQS and N = nS(1+ 
ĳ)
 
is the planned total trial size.  In general, as ĳ moves away from unity, the required 
sample size will increase. 
Community Based Exercise Programme [21] 
In this trial, 8 clusters for Control and 4 for Test were used for evaluating the programme 
as budgetary constraints limited the number of Test facilities (clusters) available whereas: 
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³«WKHUHODWLYHFRVWVRILQFOXGLQJFRQWUROVZHUHYHU\VPDOO«´ Thus instead of using a 
1:1 design, with 4 clusters, per intervention, a 2:1 allocation using 12 clusters enabled a 
larger trial with greater power to be conducted without increasing the number of T 
clusters, kT. 
 
Non-aggregate and Aggregate designs 
$µQRQ-DJJUHJDWH¶GHVLJQXVHVWKH individual observations as the unit of analysis and so 
the regression models may be extended to account for individual covariate values such as, 
for example, subject gender, age, disease severity or a pre-randomisation (baseline) 
measure of the chosen endpoint for the trial.  T the analysis will be based on an extension 
of the random effects regression model (4).  The objective of the sample size calculation 
is to determine the appropriate number of subjects required per intervention, nS and nT 
and the number of clusters is determined on division by the anticipated number of 
subjects per cluster.   
$QµDJJUHJDWH¶or µILHOG¶ design is one in which a summary measure from each cluster 
is obtained.  For example with continuous data, and n = mk subjects in each intervention, 
the trial will provide k cluster means ݕത଴ଵᇱݕത଴ଶᇱ ǥ ǡ ݕത଴௞ (each based on m observations) with 
the mean of these means for intervention x = 0 compared with those from x = 1.  In the 
situation when k is small, the analysis may use the t-test (rather than the z-test) and so the 
sample size calculations will be based on equation (1) but replacing the anticipated SD, 
ıPlan, by the anticipated standard deviation of  the summary measure, such as the mean. 
This will usually be available from prior studies and obviates the need for a design effect.  
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In this situation, m is fixed by the design team and the calculation provides the required 
number of clusters, K = 2k. 
However, although the analysis for both designs appears to be the same the number of 
degrees of freedom, df, differ.  For an aggregate design, with fixed cluster size m, 
dfAggregate = {N/m} ± 2 while for a non-aggregate design, dfNon-Aggregate = {N/DE} ± 2 = 
{N/[1+(m  1)ȡ]}  2 which is smaller larger except in the improbable situation of ȡ = 1.  
This means that correcting for small sample size has a greater effect on aggregate designs 
since the df will also be smaller.  
SAMPLE SIZE FOR CLUSTER TRIALS 
Continuous endpoint 
Non-aggregate design 
For the model of equation (4) the variance for individuals in each cluster within each 
intervention group is assumed the same, and of the form: ܸܽݎ൫ݕ௜௝൯ ൌ ߪ஻௘௧௪௘௘௡ି஼௟௨௦௧௘௥ଶ ൅ ߪௐ௜௧௛௜௡ି஼௟௨௦௧௘௥ଶ ൌ ߪ்௢௧௔௟ଶ         (8) 
If planning values for ıBetween-Cluster and ıWithin-Cluster can be provided by the design 
team, then the planned values for ıTotal  (denoted ıPlan ) and the ICC can be obtained from 
equation (5).  Alternatively values for the ICC may be obtained from previous 
experience.  In either case, although m needs to be pre-specified, DE can be determined 
and equation (1) is modified to become:   ݊ௌ ൌ ܦܧ ൈ ቀଵାఝఝ ቁ ሺ௭భషഀȀమା௭భషഁሻమሺఋು೗ೌ೙Ȁఙು೗ೌ೙ሻమ , nT = ĳQS.                              (9) 
The total sample size, N = nS + nT = Km and it follows that the required numbers of 
clusters are ݇ௌ ൌ ௄ଵାఝ and ்݇ ൌ ఝ௄ଵାఝ.  Note that the final term of equation (1), ൤ ௭భషഀȀమమଶሺଵାఝሻ൨, is 
omitted here as N is likely to be large in most circumstances.  
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Daily exercise and Quality of Life [22] 
Suppose a design team is planning a confirmatory non-aggregate cluster randomized 
trial, based on the one previously published, to see if a daily exercise regime delivered by 
personal trainers at the suggestion of their general practitioner for a year (T) would lead 
to improved quality of life compared to no intervention (S) in older men.  The primary 
outcome is the Physical Function (PF) score of the SF-36 measure at 1-year.  Previous 
experience from a cross-sectional (non-cluster) study suggests that such men have a mean 
score of 66.4 units ZLWK ıPF = 29.5 units and the effect of the daily exercise regime 
would be considered important if it increased the PF by at least 10 units. 
These lead to planning values įPlan = 10 and ıPlan = 29.5.  However, due to the high 
cost of providing personal trainers, the new design team decide on a 3:2 randomization in 
favour of the S group, that is ĳ = 2/3 = 0.6667.  This implies that K will have to be a 
multiple of 5 if the clusters are to be randomized in this ratio.  Previous experience 
suggests that an achievable cluster size is m = 30 and ȡ = 0.01 so that DE = 1 + [(30  1) 
u 0.01] = 1.29.  Further the investigators set a two-sided Į = 0.05, ȕ = 0.1, and so the 
sample size required from equation (9) is:  ݊ௌ ൌ  ?Ǥ ? ?ൈ ቀଵା଴Ǥ଺଺଺଻଴Ǥ଺଺଺଻ ቁ ൈ ሺଵǤଽ଺ାଵǤଶ଼ଵ଺ሻమሺଵ଴ȀଶଽǤହሻమ ൌ  ?Ǥ ? ?ൈ  ? ? ?Ǥ ? ? = 294.89 or 295 and nT = 
0.6667 u 295 = 196.67 or 197.  The planned total sample size is N = 295 + 197 = 492 
men.  Then with m = 30, this implies K = 492/30 = 16.4 or 17 clusters.  If the 
investigators set kS = 10 and kT = 7 then the ratio 10:7 is not dissimilar to 9:6 the 
stipulated randomization ratio of 3:2. 
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If the approach of (2) had been used then, for equal allocation n = 236, so that for ĳ = 
0.6667, ݊ௌ ൌ ଶଷ଺ൈሺଵା଴Ǥ଺଺଺଻ሻଶൈ଴Ǥ଺଺଺଻  = 236 ×1.250 = 295 and ்݊ ൌ ଶଷ଺ൈሺଵା଴Ǥ଺଺଺଻ሻଶ  = 236 ×0.833 = 
197 as previously obtained. 
 
Aggregate design 
If an aggregate design is considered, then the summary mean, ݕത௜, calculated from the m 
subjects within the cluster i, is the endpoint of concern.  In this case,  ܸܽݎሺݕത௜ሻ ൌ ߪ஻௘௧௪௘௘௡ି஼௟௨௦௧௘௥ଶ ൅ ఙೈ೔೟೓೔೙ష಴೗ೠೞ೟೐ೝమ ௠ ,                         (10) 
which can be alternatively expressed more compactly as ܸܽݎሺݕത௜ሻ ൌ ஽ாఙ೅೚೟ೌ೗మ௠ .                                                                  (11) 
The sample size now refers to the number of clusters required.  However, equation (9) 
is still used but with kS, kT and K replacing nS, nT and N.  Further, as the resulting number 
of clusters may be small, the comparison of means between the interventions will be 
made using the t-test.  In which case, z1Į/2 and z1ȕ from the Normal distribution should 
be replaced by the corresponding quantities for the t-distribution.  However, these values 
depend on the degrees of freedom (df) which are K ± 2.  At the preliminary stage we do 
not know K.  So the process begins by estimating kS (and kT) using equation (9) to obtain 
an initial value say K0 for the required total number of clusters, so df0 = K0  2.  Tables of 
the t-distribution give the values tdf0,1Į/2 and tdf0,1ȕ which are substituted for z1Į/2 and 
z1ȕ in equation (9) to obtain a revised total number of clusters, K1.  If this is different 
from K0, the degrees of freedom are recalculated as df1 = K1  2 and the process repeated 
until the value of K stabilizes. 
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In practice in 1:1 (ĳ = 1) randomization designs, if K0 t 20, the process is unlikely to 
be required while if K0 < 20 the refinement generally leads to 2 more clusters being 
added.  Thus, the process of refining the sample size in this way is effectively the same as 
the simpler one of including the final term of equation (1), which is ൤ ௭భషഀȀమమଶሺଵାఝሻ൨.   
 
Daily exercise and Quality of Life [22] 
Had the previous example been designed as an aggregate cluster trial, then with the 
information provided as ıTotal = 29.5 and ȡ = 0.01, equation (5) can be used to obtain  
2 2
Between Cluster TotalV U V  u   0.01 u (29.5)2 = 8.70 and 2 2 2Within Cluster Total Between ClusterV V V     
(29.5)2 ± 8.70 = 861.6.  Hence, if we assume m = 30, equation (10) gives ߪ௉௟௔௡ ൌට ?Ǥ ? ?൅ ଼଺ଵǤ଺ଷ଴ ൌ  ?Ǥ ? ? and, from equation (1) with ĳ = 2/3, ݇ௌ ൌ ቀଵା଴Ǥ଺଺଺଻଴Ǥ଺଺଺଻ ቁ ൈሺଵǤଽ଺ାଵǤଶ଼ଵ଺ሻమሺଵ଴Ȁ଺Ǥଵଶሻమ ൌ 9.84 or 10 clusters and kT = ĳNS = 0.6667 u 10 = 6.7 or 7 clusters giving a 
total of K = 17 in all as in the non-aggregate design.   
However, as the number of clusters is relatively small, including the final term of 
equation (1), adds 
2 2
1 /2 1.96 1.15
2(1 ) 2(1 0.6667)
z D
M
      or about 1 cluster per intervention 
to give K = 19. 
If the approach of (2) had been used then, with equal allocation k = 8.82, so that for ĳ 
= 0.6667, ݇ௌ ൌ ଼Ǥ଼ଶൈሺଵା଴Ǥ଺଺଺଻ሻଶൈ଴Ǥ଺଺଺଻  = 11.03 or 12 and ்݇ ൌ ଼Ǥ଼ଶൈሺଵା଴Ǥ଺଺଺଻ሻଶ  = 7.35 or 8 to give 
K =20. 
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Binary outcome  
Non-aggregate design 
For a binary outcome the dependent variable yij of equation (4) only takes the values 0 or 
1 with the probability ʌi that yij = 1 and which is assumed constant for each subject within 
a cluster.  Such data are analysed using a random effects logistic regression model in 
which, because of the clusters, Ȗ is retained but is assumed to come from either a Normal 
or Beta distribution, while İ is assumed to come from a Binomial distribution. [23] 
In order to calculate a sample size, the anticipated proportions responding in each 
intervention group, SS and ST need to be anticipated, from which įPlan = ST ± SS.  It is 
usual to assume that ߪ௉௟௔௡ ൌ  ඥߨതሺ ? െ ߨതሻ ,                                                   (12) 
where ߨത ൌ గೄାగ೅ଶ . 
Also required is the intra-class correlation, ȡBinary, for use in the expression DE of 
equation (5).  This can be obtained from  
2 2
2 (1 )
Between Cluster Between Cluster
Binary
Total
V VU V S S
    .                         (13) 
Finally the sample size for this situation is calculated from equation (9) but using the 
effect size, įPlan = ST ± SS, and ıPlan as specified in equation (12). 
 
Control hypertension and hypercholesterolemia [20] 
If a similar non-aggregate trial is planned on the basis of STITCH2, assuming m = 50 
subjects will be included from each general practitioner (GP), then planning values for S, 
the proportion achieving target, might be assumed as 0.40 while that for T as 0.52.  From 
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these, įPlan = 0.52 ± 0.40 = 0.12, 0.52 0.40 0.462S
   and ߪ௉௟௔௡ ൌ ඥ ?Ǥ ? ?ሺ ? െ  ?Ǥ ? ?ሻ = 
0.4984.  Further assuming ȡBinary = 0.06200.071 (derived from results of the STITCH trial 
using equation (14) below) equation (5X) gives DE = [1 + (50 ± 1) u 0.062] = 4.038.  
Finally from equation (9), with two-sided Į = 0.05 and ȕ = 0.2, ݊ௌ ൌ ்݊ ൌ  ?Ǥ ? ? ?ሾ ? ൅ሺ ? ?െ  ?ሻ ൈ  ?Ǥ ? ? ?ሿ ൈ ሺଵାଵሻଵ ሺଵǤଽ଺ା଴Ǥ଼ସଵ଺ሻమሺ଴ǤଵଶȀ଴Ǥସଽ଼ସሻమ  = 1212.91093.5 implying N = 24262188 subjects 
in total.  The corresponding number of clusters K = 24262188/50 = 4944 which may be 
increased to 50 to allows a 1:1 randomization.   
 
The preliminary estimate of sample size may have to be revised to account for 
possible variation in cluster size, non-participation of some of the clusters, and/or reduced 
numbers of individuals completing the assessments. 
 
Control hypertension and hypercholesterolemia [20] 
Thus, as was the case in the original STITCH2, if the number recruited per GP was likely 
to vary then a conservative application of equation (7) would lead to increasing the 
number of GPs by 14%.  Hence, the number of clusters becomes K = 4944 u 1.14 = 
55.950.2 or 5652 in practice.  The number of patients is thereby increased to N = 5652 u 
50 = 2,8002,600. l 
Equally, although 52 GP were identified for STITCH2, as only 44 (85%) eventually 
participated in the trial this implies that in future trials the initial planning number of 
clusters might be increased by 15% suggesting here that to 56 × 1.15 | 64 to include 52 / 
0.85 | 62 GPs and hence 62 u 50 = 3,100 patients.  
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Further, as a precautionary measure to account for potential patient (not cluster) loss, 
an approximate 15% (ș = 0.85) increase in this number may be adopted, in which case N 
= 2,800/0.85 | 3,300 may be targeted., it might be assumed that only 90% of patients will 
comply, so a commensurate increase in the number to recruit to N = 3,100/0.90 | 3,444.4 
may be considered. 
Alternatively, the DE itself may be adjusted to give a reduced value as ܦܧ ൌሼ ? ൅ሾሺ ? ?ൈ  ?Ǥ ?ሻ െ  ?ሿ ൈ  ?Ǥ ? ? ?ሽ= 3.728 replacing 4.038 of the preliminary calculations.  
Thus the revised number of subjects becomes  ?ǡ ? ? ?ൈ ଷǤ଻ଶ଼ସǤ଴ଷ଼ ൌ2,862.0 which is smaller 
than the first revised method estimate of 3,444.4.  A compromise suggests that about 
3,150 patients are required. 
Further discussion by the design team may then suggest 52 GPs should be approached, 
from which 55 patients would be recruited to the trial. 
Should all three possibilities have to be accounted for then the planned trial size may 
be designed to recruit up to (say) 4,000 individuals with consequent increases in either, 
m, K or both.  
 
Aggregate design 
In an aggregate design, each cluster within each intervention provides a single proportion, 
pxi, calculated from the m patients within that cluster.  These proportions correspond to 
the ݕത௫௜ of the continuous measure situation albeit now confined to values between 0 and 
1. 
The corresponding variance of each cluster proportion, pxi, is:  ܸܽݎሺ݌௫௜ሻ ൌ ߪ஻௘௧௪௘௘௡ି஼௟௨௦௧௘௥ଶ ൅ గഥሺଵିగഥሻଶ௠ Ǥ                           (14) 
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Control hypertension and hypercholesterolemia [20] 
The report of the STITCH2 states ³7KH SULPDU\ DQDO\VLV FRPSDUHG WKH SURSRUWLRQ RI
participants achieving targets [for example, specified blood pressure levels] between the 
two treatment groups using a two-sample t-WHVW DW WKH OHYHO RI WKH FOXVWHU « ´  7KLV
clearly indicates an aggregate design was planned and that the individual cluster 
proportion is regarded as a continuous outcome.  In addition, they specify, ıTotal = 0.15 
which is taken as ıPlan and by including the simple adjustment in equation (1), the 
number of clusters required are ்݇ ൌ ݇ௌ ൌ ଵାଵଵ ሺଵǤଽ଺ା଴Ǥ଼ସଵ଺ሻమሺ଴ǤଵଶȀ଴Ǥଵହሻమ ൅ ଵǤଽ଺మଶሺଵାଵሻ = 25.49 or 26 per 
intervention and K = 52.   
Further, using equation (14), this leads to ߪ஻௘௧௪௘௘௡ି஼௟௨௦௧௘௥ଶ ൌ  ?Ǥ ? ?ଶ െ ଴Ǥସ଺ሺଵି଴Ǥସ଺ሻଶൈହ଴  = 
0.0200 0.017.  Further and from equation (13), ȡBinary = 0.02000.017/(0.46 u 0.54) = 
0.062 0.071 as we had noted earlier.  By including the simple adjustment in equation (1), 
the number of clusters required are ்݇ ൌ ݇ௌ ൌ ଵାଵଵ ሺଵǤଽ଺ା଴Ǥ଼ସଵ଺ሻమሺ଴ǤଵଶȀ଴Ǥଵହሻమ ൅ ଵǤଽ଺మଶሺଵାଵሻ = 25.49 or 26 
per intervention and K = 52.  
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Ordinal outcome  
Non-aggregated design 
In some situations a binary outcome may be extended to comprise an ordered categorical 
variable of G (>2) levels.  In which case the two interventions are compared using 
ordered logistic regression.  Further, only non-aggregate designs are likely as individual 
cluster summaries (needed for an aggregate design) take the form of a G-level tabulation 
rather than a single measure.   
In principle, if the underlying measure is categorical then any comparisons between 
groups will be more sensitive than if a binary outcome is chosen.  Consequently for given 
Type I and Type II errors the numbers of patients required will usually be smaller.  In 
practice, there is little statistical benefit to be gained by having more than G = 5 ordered 
categories [24].  Thus, although there are G = 23 categories in the Hospital Anxiety and 
Depression Scale (HADS), with a low score as a desirable outcome [25], the data might 
be reduced to five for planning purposes (Table 2).  When considering a new trial that is 
aimed at reducing HAD scores, investigators could use these data to provide planning 
values for S.   
Although an ordinal scale outcome is envisaged, at the initial planning stages, 
investigators may first think in binary terms and, for example, consider the (cumulative) 
proportion with HADS d 7 of 60.39% with S might be improved by 10% to 70.39% using 
T.  This įPlan = 0.1 is then expressed as the planning odds ratio of 
0.7039 (1 0.7039) 1.56
0.6039 (1 0.6039)PlanOR
   .  
The basic assumption when considering the range of categories is that, wherever the 
investigators make the binary cut (in this example at 3, 7, 10 or 15), the same 
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planning OR applies [26].  Thus had the cut been made at HADS d 10, then the 
cumulative proportion with S is 0.8182 would imply that, if the ORPlan = 1.56, this 
proportion would increase to 0.8753 with T.   
The process of calculating the sample size begins by using the observed proportions 
for S as the planning values SS0, SS1, SS2, SS3, then with the design ORPlan calculate those 
anticipated for T as ST0, ST1, ST2, and ST3.   
,QJHQHUDOLIWKHFDWHJRULHVDUHGLFKRWRPL]HGE\LQFOXGLQJWKHFDWHJRULHV«g, in 
one group, and the remainder g + 1, g «G categories in the other, then a general 
expression for the odds ratio is ܱܴ௚ ൌ ஼೅೒Ȁሺଵି஼೅೒ሻ஼ೄ೒Ȁሺଵି஼ೄ೒ሻ, g > 0.                                                             (15) 
where CSg and CTg are the cumulative proportions in the S and T groups respectively.  If 
all the ORg are assumed to be equal to ORPlan then equation (15) can be rearranged to give ܥ்௚ ൌ ைோು೗ೌ೙஼ೄ೒ைோು೗ೌ೙஼ೄ೒ାሺଵି஼ೄ೒ሻ.                                                            (16) 
Once all the CTg are obtained from equation (16), the corresponding ʌTg are calculated 
by subtraction as in Table 2, for example, ʌT1 = CT1  CT0 = 0.7039 ± 0.3766 = 0.3274. 
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Table 2 Deriving the anticipated proportions within each category for the Test intervention calculated from that anticipated 
for patients in the Standard with an assumed planning odds ratio, ORPlan = 1.56. 
 
  Outcome   
  HADS score   
 0-3 4-7 8-10 11-15 16-22  
g 0 1 2 3 4  
Standard s0 = 43 s1 = 50 s2 = 33 s3 = 24 s3 = 4 nS = 154 
pSg =sg/nS pS0 = 0.2792 pS1 = 0.3246 pS2 = 0.2143 pS3 = 0.1558 pS4 = 0.0260  
Planning ʌS0 = 0.2792 ʌS1 = 0.3246 ʌS2 = 0.2143 ʌS3 = 0.1558 ʌS4 = 0.0260  
CSg CS0  ʌS0  
= 0.2792 
CS1  ʌS0+ʌS1 
 = 0.6039 
CS2  ʌS0+ʌS1+ʌS2  
= 0.8182 
CS3  ʌS0+ʌS1+ʌS2+ʌS3 
 = 0.9740 
CS4 =  
1 
 
Test       
CTg CT0  
= 0.3766 
CT1 
 
= 0.7039 
CT2  
= 0.8753 
CT3  
= 0.9832 
CT4 
 =  1 
 
ʌTg ʌT0 = 0.3766 ʌT1= 0.3274 ʌT2 = 0.1713 ʌT3 = 0.1079 ʌT4 = 0.0168  
(ʌSg+ʌTg)3 (0.2792 + 0.3766)3 
= 0.2820  
(0. 3246 + 0.3274)3 
= 0.2772 
(0.2143 + 0.1713)3 
= 0.0573 
(0.1558 + 0.1079)3  
= 0.0183 
(0.0260 + 0.0168)3 
= 0.0001 
Total  
0.6349 
     ī ± (0.6349/8) = 0.9206  
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The expression for calculating sample sizes for comparing two interventions using 1 
clusters with individual subject responses from G ordered categories is [24]: 2 ݊ௌ ൌ ܦܧ ൈ ቄଷ୻ ቀଵାఝఝ ቁ ሺ௭భషೌȀమା௭భషഁሻమሺ୪୭୥ைோು೗ೌ೙ሻమ ቅ, ்݊ ൌ ߮݊ௌ,                         (17) 3 
where 4 Ȟ ൌ ቂ ? െଵ଼  ? ሺߨௌ௚ ൅ ߨ்௚ሻଷீିଵ௚ୀ଴ ቃ.                           (18) 5 
,QFHUWDLQFLUFXPVWDQFHVWKHFDOFXODWLRQIRUīFDQEHVLPSOLILHG7KXVLIG !ī| 1, 6 
while if all ʌSg + ʌTg DUHDSSUR[LPDWHO\HTXDOWKHQī| 1  1/G2.  7 
Improvement in HADS score [25] 8 
Assuming investigators plan a cluster trial on the basis of the information of Table 2 with 9 
anticipated effect size ORPlan = 1.56, then log ORPlan = 0.4447 and equation (18) JLYHVī10 
= 0.9206.  Further assuming m = 30 with sd(m) = 0, ȡ = 0.001, then DE = 1 + (29 u 11 
0.001)] = 1.029.  Finally the investigators set ĳ = 1, two-sided Į = 0.05, ȕ = 0. 2 and 12 
obtain from equation (17) ݊ௌ ൌ ்݊ ൌ  ?Ǥ ? ? ?ൈ ቄ ଷ଴Ǥଽଶ଴଺ ቀଵାଵଵ ቁ ሺଵǤଽ଺ା଴Ǥ଼ସଵ଺ሻమሺ଴Ǥସସସ଻ሻమ ቅ = 1.029 u 13 
258.68 = 266.17.  To be divisible by m = 30 this is rounded to 270 to give N = 2 × 270 = 14 
540 subjects and K = 540/30 = 18 clusters with 9 per intervention.  15 
 16 
Incidence Rate outcome 17 
Aggregate design 18 
In some situations, all the m individuals within each cluster are followed-up for a fixed 19 
period (say F years) and the number of occurrences of a specific event is recorded among 20 
the individuals within that time.  If r i individuals in cluster i experience the event then the 21 
event rate per-person-years is estimated by Oi = ri / (m u F).  In other situations, each of 22 
the m subjects within cluster i may have different follow-up times, say, fij, in which case 23 
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the incidence rate for cluster i is ߣ௜ ൌ ݎ௜ ௜ܻ ? , where ௜ܻ ൌ  ? ௜݂௝௝  is the anticipated total 1 
follow-up time recorded for the cluster.  In practice, the incidence rate may be expressed 2 
as per-person, per-100- or per-1000-person days, years or other time frames depending on 3 
the context.  4 
An aggregate design is the usual option as it is the rate provided from each cluster 5 
which will be the unit for analysis.  In this case, an alternative to the ICC as a measure of 6 
how close individuals responses are within a cluster is the coefficient of variation, 7 
cv(Rate) = SD(Cluster Rates within an Intervention)/Mean(Rate for that Intervention), 8 
for the aggregated outcome of concern [10].  This should not be confused with CV(m) of 9 
the individual cluster sizes defined previously and used in equation (7). 10 
In designing a cluster trial, the investigators would need to specify planning values OS 11 
and OT for the mean incidence rates of the interventions, the corresponding cvS and cvT 12 
(often assumed equal), as well as the maximum duration of follow-up, F, of the 13 
individuals in the clusters.  The number of clusters required is: [10, 27]  14 ݇ௌ ൌ ቄቀఒೄାఝఒ೅௠ிఝ ቁ ൅ ሺܿݒௌଶሻߣௌଶ ൅ ሺܿݒௌଶሻߣௌଶቅ ሺ௭భషഀȀమା௭భషഁሻమሺఒೄିఒ೅ሻమ ൅ ൤ ௭భషഀȀమమଶሺଵାఝሻ൨, ்݇ ൌ ߮݇ௌ.   (19) 15 
The ൤ ௭భషഀȀమమଶሺଵାఝሻ൨ of equation (19) is the adjustment for when the number of clusters is small. 16 
If subjects are only followed up to when the event of interest occurs then mF in 17 
equation (19) may be replaced by Y, the anticipated cumulative follow-up time that will 18 
be recorded in every cluster.   19 
Left ventricular systolic dysfunction [6] 20 
The results from a trial concerned with attempts to improve outcome for patients with left 21 
ventricular systolic dysfunction suggested that Usual care (S) was associated with a 7.2 22 
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deaths per 100 years (OS = 0.072).  It is hoped that Enhanced care (T) might reduce this 1 
by 20% (OT = 0.0576).  A 1:1 cluster trial is planned with two-sided Į = 0.05, ȕ = 0.2, m = 2 
12, F = 5 years, and cvS = cvT = 0.1.  Use of equation (19) results in kS = kT = 86, so that a 3 
total of K = 172 primary care units are required.  Had more variation been anticipated, 4 
perhaps cvS = cvT = 0.2, then K = 192.  5 
 6 
Time-to-event outcome 7 
Non-aggregate design 8 
Rather than merely counting the number of events (as for the incidence rate) if the 9 
individual times to the event (often termed survival times) are recorded and used in the 10 
analysis the usual summary for each intervention is the Kaplan-Meier survival curve.  11 
The comparison between interventions is then made using Cox proportional hazards 12 
regression model [23] including a random effects term to account for the cluster design.  13 
This analysis provides an estimate of the corresponding hazard ratio (HR) which 14 
summarises the relative survival difference between the groups.  A HR = 1 corresponds to 15 
the null hypothesis of no difference.   16 
For planning purposes, it is usual to specify ȖS and ȖT which are the anticipated 17 
proportions of subjects alive at a fixed time-point beyond the date their cluster was 18 
randomised.  Once the design team has specified these, then the planning HR can be 19 
calculated from  20 ܪܴ௉௟௔௡ ൌ ୪୭୥ఊ೅୪୭୥ఊೄ                                                                             (20) 21 
The number of subjects required is [28]  22 ݊ௌ ൌ ܦܧ ൈ ቀଵఝቁ ቀଵାఝுோଵିுோ ቁଶ ሺ௭భషഀȀమା௭భషഁሻమሾሺଵିఊೄሻାఝሺଵିఊ೅ሻሿ and ்݊ ൌ ߮݊ௌ,         (21) 23 
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to give a total sample size N = nS + nT.  The ICC is difficult to estimate for survival data, 1 
but one suggestion [11, p64] is to treat the data as binary to get the ICC. In general we 2 
would recommend using a range of ICCs as the authors in the following example did. 3 
 4 
Heart dysfunction  5 
In the Trial of Education And Compliance in Heart (TEACH) dysfunction trial [7] the 6 
investigators anticipated that the 1-year rate of re-hospitalisation following earlier 7 
hospital admission for heart problems (S) would be about 75%.  It was further anticipated 8 
that this could be reduced to 60% using enhanced education on their condition from their 9 
home pharmacist (T).  Thus, with ȖS = 0.75 and ȖT = 0.60 representing the anticipated 10 
proportions re-admitted at 1-year, equation (20) gives  ܪܴ ൌ ୪୭୥଴Ǥ଺଴୪୭୥଴Ǥ଻ହ ൌ  ?Ǥ ? ? ? ?.  Further, 11 
if we take, as the investigators did, m = 2, ĳ = 1, Į = 0.05 and ȕ = 0.2 then, for a non-12 
aggregate design, equation (21) becomes 13 ݊ௌ ൌ ሾ ? ൅ ሺ ? െ  ?ሻߩሿ ൈ ቀଵଵቁ ቀଵାଵǤ଻଻ହ଻ଵିଵǤ଻଻ହ଻ቁଶ ሺଵǤଽ଺ା଴Ǥ଼ସଵ଺ሻమሾሺଵି଴Ǥ଺଴ሻାሺଵି଴Ǥ଻ହሻሿ = 154.63 × (1 + ȡ). 14 
Setting ȡ equal to 0.05 and 0.10, as the investigators did, gives the respective values of 15 
N = nS + nT  = 2 u 163 = 326 and 342 with the corresponding total number of pharmacies 16 
(clusters) required as K = 326/2 = 163 and 171 respectively.  To allow a 1:1 17 
randomisation, these are then increased to 164 and 172 to give either 82 or 86 pharmacies 18 
per intervention. 19 
 20 
Aggregate design 21 
For an aggregate design, the endpoint will be the survival rate at a fixed time following 22 
randomisation, say at the 1-year follow-up.  The planning values for these rates, say ȖS 23 
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and ȖT, are then taken as ʌS and ST and used in the same way as for sample size 1 
calculations of a binary endpoint cluster design.  2 
Matched designs 3 
In the preceding sections the individual clusters participating in the trial have been 4 
identified and then randomised (say) in equal numbers to receive the S or T intervention.  5 
However, if the clusters themselves are of variable size, then an alternative method of 6 
allocation is first to rank these clusters in terms of their size, and then create cluster pairs 7 
RIDVLPLODUVL]H2QFHWKHVHµPDWFKHG¶SDLUVDUHLGHQWLILHGWKHDOORFDWLRQof T is made at 8 
random to one of the pair and the other is then automatically assigned to S.  Options, 9 
other than size, may be used to create the matched pairs.  The choice being perhaps 10 
related to features of the clusters concerned; such as their location in Rural or Urban 11 
areas. 12 
Once the trial is complete, the difference in summary measure from each matched pair 13 
of clusters will be calculated.  Thus a matched design implies an aggregate design.  Thus, 14 
for example, if the endpoint is continuous this measure will be the difference, ݀௜ ൌ ݕത௜் െ15 ݕത௜ௌ. for each of the cluster pairs, KPairs.  From these values the mean difference ҧ݀ is 16 
obtained and this estimates the true difference between the interventions, į.  The paired t-17 
test then tests the null hypothesis į = 0.  18 
However the values of ݕത௜் and ݕത௜ௌ from the matched clusters may be themselves 19 
associated.  If, in a completed trial involving KPairs, the individual values of ݕത௜் and ݕത௜ௌ 20 
are available then their correlation, Ș, may be calculated and used for future planning 21 
purposes.  It is recommended [10] that, Ș, replaces the ICC, ȡ, in the DE of equation (6).  22 
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Nevertheless it should be recognised that, unlike for the ICC, we know of no published 1 
values of Ș.  In this situation, the number of cluster pairs required is:   2 ܭ௉௔௜௥௦ ൌ ܦܧ ൈ ൜ଶ൫௭భషഀȀమା௭భషഁ൯మሺఋು೗ೌ೙Ȁఙು೗ೌ೙ሻమ ൅ ൤௭భషഀȀమమ ଶ ൨ൠ.                                     (22) 3 
Here ıPlan is the anticipated standard deviation of the differences, di, obtained from the 4 
cluster pairs.  As the number of cluster pairings is likely to be relatively small the 5 
correction term ൤௭భషഀȀమమ ଶ ൨ is added [10]. 6 
With little or no prior knowledge of either Ș, ıPlan or both the design team would need 7 
to consider a range of options before deciding on the number of cluster pairs to include.   8 
 9 
Daily exercise and Quality of Life [22] 10 
If we suppose this planned trial was to involve communities with very diverse socio-11 
economic characteristics, then the design time might wish to create cluster pairs with 12 
similar features.  The anticipated improvement in PF with T over S is assumed the same 13 
with įPlan = 10 units.  However the previous trial provided a planning value of 6.12 units 14 
whereas for a matched design ıPlan might be anticipated to be smaller than this to an 15 
extent depending on the numbers to be recruited per cluster, m.  Thus a range of values 16 
for ıPlan, as well as Șare investigated.   17 
As a first step, the investigators take Ș = 0.01 and ߪ௉௟௔௡ ൌ  ?Ǥ ? ? and, from equation 18 
(22), with m = 30, two-sided D = 0.05 and ȕ = 0.1 obtain, ܭ௉௔௜௥௦ ൌ ሾ ? ൅ሺ ? ?െ  ?ሻ ൈ19  ?Ǥ ? ?ሿ ൈ ቄଶሺଵǤଽ଺ାଵǤଶ଼ଵ଺ሻమሺଵ଴Ȁ଺Ǥଵଶሻమ ൅ ቂଵǤଽ଺మଶ ቃቅ = 7.55 or 16 clusters which are then matched in pairs.  20 
If Ș = 0.05 then the number of cluster pairs increases to KPairs = 15.  A reduced ߪ௉௟௔௡ ൌ21  ?Ǥ ? ? results in KPairs = 4 and 8 for Ș = 0.01 and 0.05respectively. 22 
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Conclusion 1 
Cluster trials consume considerable logistical and other resources, so a critical factor is to 2 
determine the appropriate size for the trial in question.  As subjects are not individually 3 
randomised to the interventions but are allocated in clusters then this feature needs to be 4 
accounted for in both the planning and the statistical analysis.  In some instances, the 5 
number of clusters available may be fixed, in others the number of subjects per cluster is 6 
fixed or possibly both may be open to choice.  Although 1:1 allocation of interventions is 7 
usual, there is nevertheless a decision to be made with respect to this ratio.  8 
As in individually randomized trials, the two-sided test-size (Į) is conventionally set at 9 
0.05, whereas the power (1  ȕ) is often set at 0.8 although a higher value (say 0.9) is 10 
more desirable.  Further each design team will have to decide on the anticipated effect 11 
size (the difference between S and T) which will be very context specific but should 12 
reflect a realistic and clinically important difference between the groups.  However, in the 13 
cluster trial situation an ICC (or some other measure of the lack of independence of the 14 
subjects within a cluster) will need to be specified.  In some situations, cluster trials may 15 
have been done in similar circumstances to that in planning, so that the magnitude of such 16 
measures may be well documented.  However in most situations some (often 17 
considerable) judgment is required.  In either case the design team will need to consider 18 
the impact on sample size of a range of options for this (and other design features) before 19 
deciding the final trial size.  The investigators too will need to verify what will be 20 
required by CONSORT [29] for reporting their trial to ensure all these requirements are 21 
in place before the trial commences.  Of particular relevance here is the need for a clear 22 
but succinct justification of trial size.  Thus it is important to retain details of the way in 23 
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which, at the planning stage, the eventual trial design and size were determined. Further 1 
discussion of recent issues in the design and analysis of cluser trials is given in [30] 2 
[Conclusion word count: 340] 3 
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